AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Earnings are out

ANAB · NASDAQ · Biotechnology

AnaptysBio (ANAB)

Manages Jemperli and imsidolimab royalties through GSK and Vanda partnerships.

$55.86

At close+0.57 (+1.04%)

Watchlist

In millions of USD, except per-share figures

In millions	Q2 FY23Jun 2023	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026
Revenue	3	3	9	7	11	30	43	28	22	76	108	26
Cost of revenue	33	31	34	37	42	42	43	41	38	31	−108	1
Gross profit	−29	−28	−25	−30	−31	−12	1	−13	−16	45	216	25
	11	10	18	12	9	11	10	14	11	10	149	60
Research & development	33	31	41	37	42	42	43	41	38	31	26	34
	11	10	10	12	9	11	10	14	11	10	16	26
General & administrative	11	10	10	12	9	11	10	14	11	10	16	26
Other expenses	−33	−31	−34	−37	−42	−42	−43	−41	−38	−31	108	0
Operating income	−40	−38	−42	−42	−40	−23	−10	−28	−26	35	67	−35
	0	0	0	−2	−6	−10	−12	−12	−12	−20	−17	−18
Interest income	5	5	5	5	5	5	5	4	4	3	3	3
Interest expense	4	4	5	6	11	15	17	18	20	23	20	21
Other non-operating income	−5	−5	−7	−5	−5	−5	−5	−6	−7	−3	−3	−3
Income before tax	−40	−37	−42	−44	−47	−33	−22	−39	−39	15	50	−53
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	−40	−37	−42	−44	−47	−33	−22	−39	−39	15	50	−53
Net income	−40	−37	−42	−44	−47	−33	−22	−39	−39	15	50	−53
EPS, basic	−$1.50	−$1.41	−$1.57	−$1.64	−$1.71	−$1.14	−$0.77	−$1.28	−$1.34	$0.52	$1.79	−$1.84
EPS, diluted	−$1.50	−$1.41	−$1.57	−$1.64	−$1.71	−$1.14	−$0.77	−$1.28	−$1.34	$0.52	$1.58	−$1.84
Weighted average shares, basic	27	27	27	27	27	29	30	31	29	29	28	29
Weighted average shares, diluted	27	27	27	27	27	29	30	31	29	29	31	29
EBITDA	−35	−32	−35	−37	−35	−17	−4	−21	−18	38	70	−31
Depreciation & amortization	1	1	0	1	1	1	1	1	1	1	1	1
EBIT	−35	−33	−35	−38	−36	−17	−4	−21	−19	38	69	−32